Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2007

Ichor Wins $2.3M Award to Assess Vaccine Candidates for Anthrax and Plague

  • Ichor Medical Systems received a two-year contract valued at over $2.3 million by the Defense Threat Reduction Agency. Ichor will assist the Biological Defense Research Directorate in the assessment of DNA vaccine candidates for anthrax and plague developed by the Navy and administered using the company’s TriGrid™ Delivery System.

    "Ichor's TriGrid represents a promising platform technology for the rapid deployment of vaccines against anthrax, plague, and other biothreat agents," states Alain Luxembourg, M.D., Ph.D., director of infectious disease programs at Ichor.

    "DNA vaccines represent an appealing immunization modality for such applications because they are relatively straightforward to design and manufacture and compatible with long-term storage," says Ichor CEO Bob Bernard. "Because of its superior ability to enhance the potency of DNA vaccines, Ichor's TriGrid is uniquely positioned to enable consistent, robust responses to such vaccines in humans."

    The new contract builds on Ichor's ongoing collaboration with the Department of Defense (DoD), exploring the potential of electroporation-based delivery to increase the effectiveness of a number of biodefense-related DNA vaccine candidates. In March, the company received $900,000 from the DOD to assist the U.S. Army in the development of a DNA vaccine for equine encephalitis.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »